{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:22:13Z","timestamp":1791235333262,"version":"4.1.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Thrombotic antiphospholipid syndrome (APS) in Childhood-onset systemic lupus erythematosus (cSLE) remains a therapeutic frontier. Here, we report the first case of telitacicept (a TACI-Fc fusion protein)- induced remission in cSLE related antiphospholipid syndrome (cSLE-APS), where targeted dual BAFF(B cell-activating factor)\/APRIL(a proliferation-inducing ligand) inhibition resolved life-threatening infarctions and achieved sustained disease control. During treatment, corticosteroids were successfully discontinued within six months, and a lupus low disease activity state (LLDAS) was maintained. Our findings indicate that telitacicept\u2019s unique ability to regulate B-cell activity could target the dual pathology of cSLE-APS, offering a new therapeutic approach for this serious condition.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1675554","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T06:55:45Z","timestamp":1770360945000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Telitacicept in the treatment of cSLE-APS: novel therapeutic perspectives on autoimmune thrombotic diseases in children"],"prefix":"10.3389","volume":"16","author":[{"given":"Jingyue","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Pediatrics, The First People\u2019s Hospital of Yunnan Province","place":["Kunming, China"]},{"name":"The Affiliated Hospital of Kunming University of Science and Technology","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhilang","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The First People\u2019s Hospital of Yunnan Province","place":["Kunming, China"]},{"name":"The Affiliated Hospital of Kunming University of Science and Technology","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The First People\u2019s Hospital of Yunnan Province","place":["Kunming, China"]},{"name":"The Affiliated Hospital of Kunming University of Science and Technology","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The First People\u2019s Hospital of Yunnan Province","place":["Kunming, China"]},{"name":"The Affiliated Hospital of Kunming University of Science and Technology","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103802","article-title":"SLE patients with childhood-onset: A nation-wide population-based study","volume":"24","author":"Kachaner","year":"2025","journal-title":"Autoimmun Rev"},{"key":"B2","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Hemost"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicenter prospective study of 1000 patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/art.40901","article-title":"The epidemiology of antiphospholipid syndrome: A population-based study","volume":"71","author":"Duarte-Garcia","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/art.42624","article-title":"The 2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"75","author":"Barbhaiya","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320950477","article-title":"Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality","volume":"29","author":"Riancho-Zarrabeitia","year":"2020","journal-title":"Lupus"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.12.011","article-title":"B-cell directed therapies in antiphospholipid antibody syndrome--new directions based on murine and human data","volume":"11","author":"Khattri","year":"2012","journal-title":"Autoimmun Rev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.02.002","article-title":"Rituximab usage in systemic lupus erythematosus-associated antiphospholipid syndrome: A single-center experience","volume":"46","author":"Wang","year":"2016","journal-title":"Semin Arthritis Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/08923973.2021.1973493","article-title":"Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease","volume":"43","author":"Shi","year":"2021","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B12","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102693","article-title":"Childhood-onset systemic lupus erythematosus-related antiphospholipid syndrome: A multicenter study with 1519 patients","volume":"19","author":"Islabao","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra002974","article-title":"The antiphospholipid syndrome","volume":"346","author":"Levine","year":"2002","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-025-07624-4","article-title":"The distinct subtypes and prognosis of acute myocardial infarction in antiphospholipid syndrome patients","volume":"44","author":"Huang","year":"2025","journal-title":"Clin Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2018.00362","article-title":"The differences between childhood and adult onset antiphospholipid syndrome","volume":"6","author":"Wincup","year":"2018","journal-title":"Front Pediatr"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae583","article-title":"ANA-positive versus ANA-negative antiphospholipid antibody-positive patients: results from the antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) clinical database and repository (\u201cRegistry\u201d)","volume":"64","author":"Cecchi","year":"2025","journal-title":"Rheumatol (Oxford)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14492","article-title":"Commentary on: Circulating plasmablasts contribute to antiphospholipid antibody production, associated with type I interferon upregulation","volume":"17","author":"Yin","year":"2019","journal-title":"J Thromb Haemost"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000001253","article-title":"Evaluation of acquired and hereditary risk factors for the development of thromboembolism in patients with systemic lupus erythematosus","volume":"34","author":"Gursoy","year":"2023","journal-title":"Blood Coagul Fibrinolysis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2006.04.006","article-title":"APRIL and their receptors: structure, function and signaling","volume":"18","author":"Bossen","year":"2006","journal-title":"Semin Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e000693","DOI":"10.1136\/rmdopen-2018-000693","article-title":"Increased B-cell activating factor (BAFF)\/B-lymphocyte stimulator (BLyS) in primary antiphospholipid syndrome is associated with higher adjusted global antiphospholipid syndrome scores","volume":"4","author":"van den Hoogen","year":"2018","journal-title":"RMD Open"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102594","article-title":"Belimumab reduces antiphospholipid antibodies in primary triple-positive antiphospholipid syndrome","volume":"19","author":"Klemm","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213496","article-title":"Anticardiolipin and anti-beta 2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on belimumab","volume":"77","author":"Sciascia","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-025-07411-1","article-title":"Effects of telitacicept in SLE patients with antiphospholipid antibody positivity: a retrospective self-controlled case series","volume":"44","author":"Zhou","year":"2025","journal-title":"Clin Rheumatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01990","article-title":"Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders","volume":"10","author":"Kaegi","year":"2019","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/all.14704","article-title":"Systematic review of safety and efficacy of belimumab in treating immune-mediated disorders","volume":"76","author":"Kaegi","year":"2021","journal-title":"Allergy"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-001074","article-title":"Efficacy and safety of telitacicept in patients with systemic lupus erythematosus: a multicenter, retrospective, real-world study","volume":"10","author":"Jin","year":"2023","journal-title":"Lupus Sci Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1675554\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T06:55:50Z","timestamp":1770360950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1675554\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":27,"alternative-id":["10.3389\/fimmu.2025.1675554"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1675554","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"article-number":"1675554"}}